| Entry |
|
|---|
| Name |
Encorafenib (JAN/USAN/INN);
Braftovi (TN) |
|---|
| Product |
|
|---|
| Formula |
C22H27ClFN7O4S
|
|---|
| Exact mass |
539.1518
|
|---|
| Mol weight |
540.0107
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG03159 BRAF kinase inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
|
|---|
| Efficacy |
Antineoplastic, BRAF kinase inhibitor |
|---|
| Disease |
Melanoma (BRAF mutation positive) [DS: H00038] Colorectal cancer (BRAF mutation positive) [DS: H00020] |
|---|
| Target |
|
|---|
| Network |
| N10007 | Kinase inhibitor to BRAF mutation |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EC B-Raf serine-threonine kinase (BRAF) inhibitors
L01EC03 Encorafenib
D11053 Encorafenib (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Encorafenib
D11053 Encorafenib (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11053 Encorafenib (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
TKL group
BRAF* [HSA_VAR:673v1]
D11053 Encorafenib (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11053
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11053
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11053
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11053
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11053
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11053
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 36
1 C8x C 13.0900 -16.2400
2 C8x C 13.0900 -17.6400
3 C8y C 14.2800 -18.3400
4 N5x N 15.5400 -17.6400
5 C8y C 15.5400 -16.2400
6 N5x N 14.2800 -15.5400
7 N1b N 16.7300 -15.5400
8 C1b C 17.9200 -16.2400
9 C1c C 19.1100 -15.5400
10 N1b N 20.3000 -16.2400
11 C7a C 21.4900 -15.5400
12 O7a O 22.6800 -16.2400
13 C1a C 23.8700 -15.5400
14 O6a O 21.4900 -14.1400
15 C1a C 19.1100 -14.1400
16 C8y C 14.2800 -19.7400
17 C8y C 13.1600 -20.5800
18 N5x N 13.5800 -21.9100
19 N4y N 14.9800 -21.9100
20 C8x C 15.4700 -20.5800
21 C8x C 9.5200 -18.4800
22 C8y C 9.5200 -19.8800
23 C8y C 10.7100 -20.5800
24 C8y C 11.9700 -19.8800
25 C8x C 11.9700 -18.4800
26 C8y C 10.7100 -17.7800
27 X F 10.7100 -21.9800
28 X Cl 10.7100 -16.3800
29 N1b N 8.3300 -20.5800
30 S4a S 7.1400 -19.8800
31 C1a C 5.9500 -20.5800
32 O3c O 8.1200 -18.9000
33 O3c O 6.0900 -18.9000
34 C1c C 15.7808 -23.0584
35 C1a C 17.1472 -23.0109
36 C1a C 15.1922 -24.3141
BOND 38
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 11 14 2
15 9 15 1 #Down
16 3 16 1
17 16 17 1
18 17 18 2
19 18 19 1
20 19 20 1
21 16 20 2
22 21 22 2
23 22 23 1
24 23 24 2
25 24 25 1
26 25 26 2
27 21 26 1
28 24 17 1
29 23 27 1
30 26 28 1
31 22 29 1
32 29 30 1
33 30 31 1
34 30 32 2
35 30 33 2
36 19 34 1
37 34 35 1
38 34 36 1
|
|---|
